INT344063

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.04
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 5
Disease Relevance 3.16
Pain Relevance 0.80

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
plasma 1
body 1
Esl1 (Mus musculus)
Pain Link Frequency Relevance Heat
Lamotrigine 25 98.36 Very High Very High Very High
headache 25 98.16 Very High Very High Very High
Gabapentin 15 98.10 Very High Very High Very High
carbamazepine 60 93.52 High High
antiepileptic Drug 95 78.08 Quite High
sodium channel 55 67.24 Quite High
anticonvulsant 10 48.00 Quite Low
Neuropathic pain 5 5.00 Very Low Very Low Very Low
amygdala 5 5.00 Very Low Very Low Very Low
gABA 5 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Dizziness 25 99.80 Very High Very High Very High
Vomiting 35 98.88 Very High Very High Very High
Diplopia 20 98.56 Very High Very High Very High
Headache 25 98.16 Very High Very High Very High
Exanthema 10 97.76 Very High Very High Very High
Convulsion 175 97.04 Very High Very High Very High
Vertigo 10 96.72 Very High Very High Very High
Fatigue 15 96.20 Very High Very High Very High
Epilepsy 120 92.88 High High
Body Weight 10 89.32 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Several in vitro studies did not reveal a major influence of warfarin, diazepam, digoxin, phenytoin, and tolbutamide on ESL plasma protein binding.
ESL Binding (binding) of in plasma
1) Confidence 0.04 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2987506 Disease Relevance 0.12 Pain Relevance 0.12
Finally, ESL was associated with very few psychiatric events, and the incidence of rash was low.12,14,16–18,24,29–31,35,40,44,45
ESL Binding (associated) of associated with exanthema
2) Confidence 0.04 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2987506 Disease Relevance 0.55 Pain Relevance 0.09
The most commonly reported adverse events associated with ESL are dizziness, somnolence, nausea, diplopia, headache, vomiting, blurred vision, vertigo, and fatigue.
ESL Binding (associated) of associated with vertigo, diplopia, vomiting, dizziness, fatigue and headache
3) Confidence 0.04 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Abstract Doc Link PMC2987506 Disease Relevance 1.48 Pain Relevance 0.19
0.001 versus ESL 400 mg and placebo), and 32.8% (ESL 1200 mg, P ?
ESL Binding (0.001) of
4) Confidence 0.03 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2987506 Disease Relevance 0.76 Pain Relevance 0.11
In healthy subjects, maximum observed plasma concentrations were attained at 1–4 hours postdose after single-dose administration, and steady-state plasma concentrations were attained at 4–5 days, reflecting a half-life of 20–24 hours.12,28 According to pharmacokinetic analyses of data from Phase III studies in adults with epilepsy, the clearance of carbamazepine, phenytoin, topiramate, clobazam, gabapentin, phenobarbital, levetiracetam, and sodium valproate seems to be unaffected by ESL Furthermore, there is a growing body of evidence that acetazolamide, clobazam, clonazepam, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone, and sodium valproate do not interfere with metabolism of ESL.16,24,28–30

Efficacy of ESL

ESL Binding (metabolism) of in body associated with epilepsy, lamotrigine, gabapentin and carbamazepine
5) Confidence 0.03 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2987506 Disease Relevance 0.17 Pain Relevance 0.29

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox